<DOC>
	<DOCNO>NCT00768729</DOCNO>
	<brief_summary>Kidney transplantation widely consider treatment choice child End Stage Renal Disease ( ESRD ) . The purpose study determine safety sirolimus monotherapy long-term immunosuppression child adolescents kidney transplantation .</brief_summary>
	<brief_title>Safety Immunosuppression Minimization Children Adolescents After Kidney Transplantation</brief_title>
	<detailed_description>Improvements surgical technique , donor selection , immunosuppression practice , enhance experience specialize pediatric transplant team lead marked improvement patient kidney graft survival infant young child Long-term graft survival rate decrease adolescents 11 17 year age . Several study suggest decrease may result noncompliance immunosuppressive medication age group . Therefore , protocol minimize use immunosuppressive medication , retain kidney function necessary improving graft patient survival child . The purpose study determine safety sirolimus monotherapy long-term immunosuppression child adolescents kidney transplantation . This study enroll 10 participant previously complete CCTPT-PC01 study . The accrual period schedule 12 month . The study follow-up period last 96 week . Patients CCTPT-PC01 study maintain sirolimus mycophenolate mofetil ( MMF ) since 2-3 month post transplant . Enrolled participant receive ( MMF ) Azathioprine study entry dose withdraw gradually period 6 month . Dosage reduce 25 % initially 25 % every 2 month result complete withdrawal 6 month . This study consist 11 study visit screen study entry . Study visit occur week 1 , 8 , 16 , 24 , 32 , 40 , 48 , 60 , 72 , 84 , 96 . A physical exam , vital sign , sirolimus level , well blood urine collection occur visit . A renal biopsy perform week 96 .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<criteria>Participant and/or parent guardian able understand willing provide inform consent Previously enrol complete CCTPTPC01 study within 36 month postcompletion timeframe prior study entry Currently receive sirolimus MMF azathioprine therapy No history acute rejection episodes No evidence acute chronic rejection 24 month CCTPTPC01 protocol biopsy subsequent biopsy obtain time prior study entry PRA ( Class I II ) less 5 % study entry No evidence donor specific antibody study entry Stable renal function GFR great 60 cc/min 1.73M^2 use Schwartz calculate method A negative pregnancy test female participant childbearing potential study entry Agreement female male participant use FDA approve method contraception . Total lymphocyte count le 400 mm^3 Acute chronic infection study entry Treatment investigational drug within 1 month prior study entry Mental illness history drug alcohol abuse , opinion investigator , would interfere study History allergic reaction Iodine GFR assay History malignancy within past 12 month Inability unwillingness give informed consent comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>End stage renal disease</keyword>
	<keyword>Kidney transplantation</keyword>
	<keyword>Renal transplantation</keyword>
	<keyword>Kidney failure</keyword>
	<keyword>Children</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Rapamycin</keyword>
	<keyword>CellCept</keyword>
	<keyword>Mycophenolate mofetil ( MMF )</keyword>
	<keyword>Azathioprine</keyword>
</DOC>